Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

NanoViricides, Inc

NNVC ✓ COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.38

▲ +1.47%

Market Cap $35.05M · Vol 10.80K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$35.05M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

33.33

Momentum

Beta

1.65

vs Market

52W High

$2.22

37.84% below

52W Low

$0.85

62.35% above

Volume

10.80K

Avg 33.40K

P/B

3.09

Price-to-book

ROE

N/A

Return on equity

Free Float

97.64%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, NanoViricides, Inc (NNVC) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NNVC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.82%

-22.03%

-20.69%

+38.00%

YTD

+22.12%

-6.12%

+2.22%

-63.68%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-9,466,970.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-87.47% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.09
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	25.40M

Technical Indicators

50-Day SMA	$1.47
200-Day SMA	$1.30
RSI (14)	33.33
Beta	1.65
52-Week High	$2.22
52-Week Low	$0.85

Volume Today	10.80K
Avg Daily Volume (30D)	33.40K
Relative Volume	0.32x
Volatility (10D)	37.31
Volatility (30D)	71.89
Free Float	97.64%

Analyst Consensus

BUY

Current Price $1.38

Mean Target $6.00

52W Low$0.85 52W High$2.22

Current

Target

$0.85 $2.22

Current Analyst target

+334.78% upside potential · 2 analysts

Identifiers

ExchangeNYSE American

FIGIBBG001SDFF62

ISINUS6300873022

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateAug 15, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.